A New Frontier in Weight Management The landscape of obesity treatment is evolving rapidly, and recent data from the REIMAGINE 5 trial has provided a compelling look at the next generation of weight-loss therapies. Novo Nordisk has shared results comparing their investigational drug, CagriSema, directly against tirzepatide (marketed as Zepbound/Mounjaro), marking a significant milestone in…